Insmed Presents Additional Data From Pivotal ASPEN Study Of Brensocatib In Patients With Bronchiectasis At The 7th World Bronchiectasis Conference
Insmed Presents Additional Data From Pivotal ASPEN Study Of Brensocatib In Patients With Bronchiectasis At The 7th World Bronchiectasis Conference
—New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo—
新的圖表描繪了52周的FEV1數據，說明Brensocatib 25 mg相對於安慰劑引起的肺功能下降明顯減少。
—Additional Exploratory Endpoints to be Presented, Including FVC and Patient-Reported BEST Score—
還將呈現其他探索性終點，包括FVC和患者報告的BEST評分。
BRIDGEWATER, N.J., July 3, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that additional positive results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis, will be presented tomorrow, July 4, 2024, at the 7th World Bronchiectasis Conference (WBC) in Dundee, Scotland. Slides from this presentation can be found here.
新澤西州布里奇沃特，2024年7月3日 /美通社/--全球生物製藥公司Insmed Incorporated (納斯達克:INSMD)於今日宣佈，將於明天2024年7月4日在蘇格蘭鄧迪舉行的第七屆世界支氣管擴張症狀大會 (WBC)上呈現ASPEN研究的附加正面研究結果。這是一項全球性的隨機雙盲安慰劑對照3期研究，旨在評估Brensocatib對非囊性纖維化支氣管擴張症患者的療效、安全性和耐受性。此演示文稿的幻燈片可在此處找到。